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ABSTRACT
We have expressed human p53 cDNA in the yeast
Saccharomyces cerevisiae and shown that the level
of production and the length of the p53 protein
depends on the presence of untranslated mRNA
regions (UTRs). The expression of the ORF alone
leads to a p53 protein of correct size (53 kDa) that
accumulates to high levels, concomitantly with the
presence of a small amount of a p40 protein (40 kDa).
However, when either the entire 5′-UTR and a part of
the 3′- or 5′-UTR alone is used, this leads to the
production of small amounts of the 40 kDa truncated
form only. The p40 protein corresponds to a trun-
cated form of p53 at the C-terminal extremity since it
reacts only with a monoclonal antibody recognising
the N-terminal epitope. This effect on the amount and
length of p53 protein had no correlation at the mRNA
level, suggesting that translational control probably
occurs through the 5′-UTR. We propose a model of
structural interaction between this UTR and a part of
the ORF mRNA for the regulation of p53 expression
in this heterologous context.
INTRODUCTION
The tumour suppressor gene p53 is mutated or deficient in 50%
of all human cancers (1–3). The disruption of p53 function is
associated with genetic instability and tumourigenesis (4). The
p53 protein plays a central role in cell cycle check-point in
response to DNA damage, triggering G1 arrest or apoptosis.
The p53 protein is a nuclear transcription factor whose target
genes are involved in cell cycle control, such as p21 CIP1/WAF1,
which inhibits cyclin-dependent pRB kinase (5,6); bax and
bcl2 genes whose products enhance and repress the apoptotic
pathway, respectively (7,8); Gadd45 gene, which may be
involved in DNA repair (9); and Mdm2 gene, which negatively
regulates p53 synthesis by mediating its proteolysis (10).
The p53 protein is active as a tetramer and the 393 amino
acid monomer is constituted by an acidic N-terminal region
containing a transactivator domain, a central DNA binding
domain and a C-terminus which includes an oligomerisation
region, a nuclear localisation signal and a site for DNA damage
recognition (for reviews see 3,11). Most of the p53 missense
mutations in tumours are located in the DNA binding domain
with four mutational hot spots affecting residues R175, R248,
R249 and R273 (12–14). In wild-type cells the p53 level is
very low compared to tumour cells where the mutant p53 is
accumulated due to an increase in its half-life from a few
minutes to several hours (15). Following DNA damage, the
wild-type p53 level increases rapidly and seems to be an
important event for the initiation of G1 arrest or apoptosis (11).
Several lines of enquiry show that p53 expression is
regulated at least in part at the translational level (16–19). It
has been shown that the murine p53 protein has the ability to
bind to the 5′-UTR and inhibit its own mRNA translation in an
in vitro assay system (20,21). On the other hand, the p53 3′-UTR
can repress translation of the corresponding mRNA and of
heterologous transcripts in cell-free extracts (22,23). The
authors have demonstrated that a negative regulatory element
in the distal end of the p53 mRNA (containing an Alu-like
sequence) is involved in this translational inhibition in vivo.
Possible interactions between RNA-binding factors and the
p53 mRNA UTR might contribute to the regulation of human
p53 mRNA translation (23).
Human p53 has been expressed in heterologous fungal
systems such as the yeast Saccharomyces cerevisiae (24) and
Schizosaccharomyces pombe (25). A growth arrest response is
observed only in this latter yeast, while in the former such
expression led to the development of the ‘fassay’, a functional
assay to screen and detect p53 mutations in cell lines, blood
and tumours (26).
In this paper, we report the effect of the 5′-UTR and part of
the 3′-UTR on human p53 expression in yeast S.cerevisiae. We
show that the expression of p53 ORF alone leads to a recombinant
protein of 53 kDa accumulating in large amounts after galactose
induction of the Gal10/cyc1 promoter, and a limited accumulation
of a shorter protein (40 kDa). However, if we express the p53
ORF with the above mentioned portions of UTRs, we obtain
only limited amounts of the p40 protein, which corresponds to
a truncated form of p53 since it is recognised specifically with
a p53 monoclonal antibody directed against the N-terminal but
not against the C-terminal epitope. The difference between the
p53 protein level in the two recombinant yeast strains was not
correlated with differences at the mRNA level since we have
shown that the p53 mRNA abundance is quite similar in the two
strains (yp53 and y∆p53). In view of this result, we suggest that
human p53 expression is controlled at a translational level via the
UTRs in this heterologous context. To identify which UTR
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was involved, we deleted the 5′- or 3′-UTR of p53 and showed
that the presence of the 3′-UTR does not affect p53 synthesis
since we obtain high levels of the 53 kDa protein. However,
when only the 5′-UTR was present, the p40 protein was
expressed at a low level, suggesting that the negative control
was exerted by the 134 bp of the 5′-UTR. We propose a
structural model to explain our results on the translational
regulation of human p53 expression in yeast S.cerevisiae.
MATERIALS AND METHODS
Strains and media
The yeast strain W303-1B (α leu2 ura3 trp1 his3 ade2 canR)
was used for transformation by LiCl procedure as described
(27).
The recombinant strains (yp53, y∆p53, y5′∆p53 and
y3′∆p53) were cultivated on minimum (0.67% yeast nitrogen
base) or rich (1% bactopeptone, 1% yeast extract) media
supplemented with 0.5% glucose as a carbon source and 2%
galactose as an inducer.
The Escherichia coli strain was DH5α (supE44∆lac U169,
hsdR17, recA1, endA1, gyrA96, thi-1, relA1). Transformation
was carried out as described (28).
Plasmids
The YepDP8-1 (provided by D.Pompon, C.G.M., CNRS-Gif
sur Yvette, France) was used as a vector to express human p53
cDNA, under the control of the Gal10/cyc1 yeast promoter.
This vector contains the 2µ replication origin and the ura3
marker. The wild-type human p53 cDNA was isolated from
pBSKII/p53 (provided by Prof. Ozturk, Bilkent University,
Ankara, Turkey) as a fragment of 1.478 kb by BamHI–KpnI.
After purification from Nusieve agarose gel (TEBU), the p53
cDNA fragment was inserted into BamHI–KpnI sites of
YepDP8-1 and the recombinant plasmid was introduced in
yeast W303-1B. To construct the p53 cDNA deleted in both 5′-
and 3′-UTR portions or in only one of each UTR, we used two
oligonucleotides covering the ATG and TGA codons. PCR was
done on 100 ng of pBSKII/p53 as follows: 30 s at 94°C, 30 s at
55°C and 2 min at 72°C for 30 cycles. The primers used were:
sense primer, 5′-GGGATCCCATGGAGGAGCCGCAGTCA;
antisense primer, 5′-GGTACCGAGTGAGTCAGTCTGAGTC.
The PCR products were analysed on a 1.2% agarose gel and
the fragments were purified on Nusieve agarose gel, cloned in
pMosblue-T vector (Amersham) and finally inserted into
BamHI–KpnI sites of the YepDP8-1, downstream of the
Gal10/cyc1 promoter.
RNA extraction and northern blot analysis
Total RNA was isolated from yeast cells collected from 100 ml
of strains yp53, y∆p53, y5′∆p53 and y3′∆p53 cultured on rich
medium containing 0.5% glucose, until OD = 3, then supple-
mented with 2% galactose to induce the Gal10/cyc1 promoter,
for 12 h. Cells (1 g) were broken with 1 g of alumina in 10 ml
TE (10 mM Tris–HCl pH 8, 1 mM EDTA) buffer. After two
phenol–chloroform extractions, nucleic acids were precipitated
overnight at –20°C with 2 vol ethanol, and RNA were
collected after precipitation by an equal volume of 8 M LiCl at
4°C. Thirty micrograms of total RNA were fractionated by
electrophoresis on a formaldehyde–agarose gel and transferred
to nylon membranes (Amersham). Filters were hybridised with
p53 cDNA 32P-labelled using a Rediprime kit (Amersham).
Hybridisations were done in 50% formamide, 1% Denhardt,
1% SDS, 6× SSC (150 mM NaCl, 15 mM sodium citrate) at
42°C overnight followed by two 10 min washes at room
temperature with 2× SSC, 0.1% SDS and two 15 min washes at
42°C in 2× SSC, 0.1% SDS.
Protein extraction and western blot
The recombinant strains yp53, y∆p53, y5′∆p53 and y3′∆p53
were cultivated on rich medium containing 0.5% glucose.
After 24 h, 2% galactose was added and the cultures were
maintained at 30°C for 12 h. Cells were collected and broken
by glass beads in 10 mM Tris–HCl pH 7.5, 1 mM EDTA pH 8,
150 mM NaCl, 1% Nonidet P-40 in the presence of protease
inhibitors (1 mM PMSF, 2 µg/ml leupeptine and 1 mg/ml
pepstatine). After centrifugation at 12 000 r.p.m. (Eppendorf)
for 15 min, the supernatant was collected and protein concen-
tration determined by Bio-Rad assay. Thirty micrograms of
total protein were separated by 10% SDS–PAGE and electro-
transferred to nitrocellulose membranes (Amersham). Immuno-
blotting was carried out with one of two primary monoclonal
anti-p53 antibodies: (i) HR53C1 (from Prof. Ozturk), which
recognises N-terminal epitope (121–130 amino acids) and was
used at 1:100 v/v dilution or (ii) Ab1 (Amersham), which
recognises the C-terminal epitope of the p53 (371–380 amino
acids) and was used at 1:100 v/v dilution.
The secondary antibody used was an anti-mouse conjugated
to alkaline phosphatase, revealed by NBT and BCIP as recom-
mended by the supplier (Bio-Rad).
RESULTS
Expression of human p53 in yeast S.cerevisiae and its effect
on cell growth
We have expressed the wild-type human p53 cDNA using the
yeast multicopy vector YepDP8-1 under the control of an
inducible promoter Gal10/cyc1. The wild-type p53 cDNA
contains, in addition to the 1190 bp of the ORF, the entire 5′-UTR
(134 bases) and the beginning of the 3′-UTR (154 bases).
With the yeast strain used, W303-1B (a non-protease-
deficient strain), a negative effect of p53 expression on yeast
cell growth is clearly shown (Fig. 1). This effect is significant
only on galactose where the Gal10/cyc1 promoter is induced. It
is significant during the latency and the exponential phases,
after which the yp53 strain follows the same growth rate as the
control W303/YepDP8-1 and reaches the same plateau at
stationary phase but slightly later on (Fig. 1). This effect could
be seen on rich as well as on minimal media (data not shown).
By northern blotting, we visualised the p53 mRNA; however,
the corresponding protein was smaller than expected (only
40 kDa) and was expressed at a low level after galactose
induction (see below and Fig. 2A).
The deletion of 5′- and 3′-UTRs of human p53 cDNA
increases its expression in yeast
It is well known that it is important to shorten the distance
between the promoter and the ATG codon as much as possible
to increase translation efficiency in a heterologous context,
henceforth in yeast. For this purpose, we constructed by PCR a
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truncated p53 cDNA (∆p53) deleted in 134 bp of 5′-UTR and
154 bp of 3′-UTR, using two primers covering the ATG and
TGA codons of the p53 ORF. The amplified ORF DNA frag-
ment of 1190 bp was sequenced to verify that no error had
occurred during Taq DNA polymerase amplification. This
shortened p53 cDNA (∆p53) was inserted in YepDP8-1 and
the p53 level in the two yeast strains (yp53 and y∆p53) was
compared by western blot analysis. Figure 2B clearly shows
that the monoclonal anti-p53 (HR53C1) recognises two
proteins in the y∆p53 strain: a 53 kDa protein, highly accumu-
lated, and a 40 kDa protein, weakly produced. Only the 40 kDa
protein could be seen in the yp53 strain (Fig. 2B). The growth
curves of both strains are strictly similar on glucose as well as
on galactose, the negative effect of p53 expression is therefore
the same in yp53 and y∆p53 (Fig. 1).
Figure 2C shows another result concerning the kinetics of
recombinant p53 expression. Yp53 and y∆p53 strains were
cultivated on 0.5% glucose until the end of the exponential
phase, then induced by 2% galactose and aliquots were taken
after 6, 12 and 24 h. The p53 is present only in y∆p53 with a
maximum level reached at 12 h whereas the p40 is present in
yp53 only at 12 h post-induction and is completely absent at
24 h. We cannot report in this experiment about its presence at
6 h in this strain because the amount of protein loaded on the
gel was very low (notice the absence of yeast proteins y1 and
y2 serving as internal controls in Fig. 2C). We verified on other
gels that in fact p40 is present at 6 h post-induction in yp53
(see, for example, Fig. 4B). Interestingly enough, at 12 and
24 h, p40 could be seen in y∆p53 strain, but it was absent at 6 h
post-induction.
According to these results, we conclude that the presence of
both 5′- and 3′-UTRs, or only one of them, has two effects on
human p53 expression in yeast: (i) the level of expression is
very low and (ii) the p53 protein is truncated. Inversely, the
deletion of both 5′- and 3′-UTRs leads to the accumulation of
high levels of a full-length 53 kDa protein. These results
prompt the following questions: (i) is the difference in the p53
Figure 1. Effect of human p53 on yeast growth. The yeast strains yp53, y∆p53
and the control (W303/YepDP8-1) were pre-cultivated on minimal medium
with 0.5% glucose for 2 days and used to inoculate rich media with either 2%
galactose (inducing condition) or 2% glucose (repressive condition). We then
measured optical density at 600 nm.
Figure 2. (A) Northern blot analysis of p53 transcripts in the yeast strains yp53
(P) and y∆p53 (∆). The lower part represents the ethidium bromide-stained gel
and the upper part shows the autoradiograph using p53 cDNA as a probe. (B) Western
blot analysis of p53 protein expression in the two recombinant yeast strains
yp53 (P) and y∆p53 (∆) using the HR53C1 p53 monoclonal antibody. (C) Kinetics
of p53 expression. The yeast strains yp53 (P) and y∆p53 (∆) were cultivated at
28°C in rich medium with 0.5% glucose, until OD = 3, then 2% galactose was
added and aliquots taken at 6, 12 and 24 h. p53 was immunoblotted for the
monoclonal antibody HR53C1. Note the cross-reaction with two yeast proteins
(y1 and y2), which serve as internal control of loading.
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protein level related to a variation in the p53 mRNA in strains
yp53 and y∆p53? (ii) Is the 40 kDA protein really a truncated
form of p53? (iii) Is there a link between the effect on the
expression level and on protein length? (iv) Is this effect
related to either the 5′- or the 3′-UTR, or to both?
Comparative analysis of p53 mRNA and protein in yp53
and y∆p53 strains
To determine whether the difference in p53 protein level in
yp53 and y∆p53 reflected a difference in the abundance of p53
mRNA, we performed northern blot analyses. Thirty micro-
grams of total RNA extracted from both strains was hybridised
with 32P-labelled p53 cDNA probe. The results show that the
relative amount of p53 mRNA is quite similar in both yeast
strains suggesting that the deletion of the 5′- and 3′-UTR
portions has no effect on p53 transcription (Fig. 2A). In
contrast, the UTRs affect the translation process since p53 is
very abundant in the y∆p53 whereas in the yp53 strain, only
the p40 form was observed and weakly expressed (Fig. 2B). In
order to verify that the shorter protein corresponds to a
truncated form of p53, we used two anti-p53 antibodies recog-
nising either the N-terminal (HR53C1) or the C-terminal part
(Ab1) of the p53 protein. Figure 3 shows that HR53C1 reacts
with both p53 and p40 proteins while the Ab1 antibody recog-
nised only the p53 in the y∆p53 strain. Therefore, we conclude
that the p40 is a p53 deleted in its C-terminal region.
Deletion of either 5′- or 3′-UTR and its effect on
recombinant p53 synthesis
To identify which UTR was involved in the translational
control of p53, we constructed two other recombinant strains,
y5′∆p53 and y3′∆p53, harbouring plasmids containing the p53
cDNA minus the 134 bp of the 5′-UTR or the 154 bp of the 3′-
UTR, respectively (Fig. 4A). By northern blot analysis, we
showed that no quantitative differences were observed at the
p53 mRNA level (data not shown). However, the p53 full-
length protein was detected only in the y5′∆p53 strain at a high
level, concomitant with a low level of the p40 while only the
truncated form (p40) was present in y3′∆p53 at a low level of
expression (Fig. 4B). Note that in Figure 4B, the p40 was not
detected in y∆p53 or in y5′∆p53; the reason is that the cells
were collected after 6 h galactose induction. As stated above, at
such time of induction, no p40 can be seen (Fig. 2C).
DISCUSSION
We carried out the expression of human p53 in yeast using a
multicopy 2µ based vector and showed that the recombinant
protein affects the cell growth rate particularly during the
latency and the beginning of exponential phases. The yp53
strain reaches the same plateau at stationary phase as the
control but after a certain lag. It was previously shown that p53
alters the cell growth in the fission yeast S.pombe (25).
However, in the yeast S.cerevisiae, Nigro et al. (24) have
previously reported that the growth inhibitory effect is
observed only in a protease deficient strain and after short-
ening the 5′-UTR, when they expressed the human p53 in a
centromeric low copy number yeast vector. This effect also
became significant if the p53 was co-expressed with the human
CDCH2 gene in a non-protease-deficient strain. Our strain is a
non-protease-deficient strain but we used is a multicopy
vector.
In this paper, we provide evidence for translational control of
human p53 expression in the yeast S.cerevisiae. We have
shown that 5′- and 3′-UTR deletion does not affect transcrip-
tion but considerably enhances the translation efficiency of
human p53 cDNA in yeast. The p53 mRNA level in both yp53
and y∆p53 strains is quite similar, hence the observed qualitative
and quantitative differences on the recombinant p53 protein
must result from alterations of the translational process.
Indeed, qualitatively, the anti-p53 antibody (HR53C1) recog-
nises a 40 kDa protein in both strains yp53 and y∆p53 and a
53 kDa protein only in y∆p53. Quantitatively, the level of the
53 kDa protein in y∆p53 is much higher than p40 in yp53.
Figure 3. Western blot analysis of p53 protein expression in the two recombinant
yeast strains yp53 (P) and y∆p53 (∆) using HR53C1 (left) and Ab1 (right) p53
monoclonal antibodies. HR53C1 and Ab1 recognise the N- and the C-terminal
regions of p53, respectively. The cultures were stopped at 12 h post-induction.
Figure 4. (A) Schematic representation of p53 constructs used in this study.
The p53 ORF (open), 5′-UTR (black) and 3′-UTR (grey) are represented.
(B) Western blot of p53 protein expression in the recombinant yeast strains
yp53 (P), y∆p53 (∆), y5′∆p53 (5′∆) and y3′∆p53 (3′∆). The cultures were
stopped at 6 h galactose post-induction. HR53C1 was used as p53 primary
monoclonal antibody.
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Using a monoclonal antibody recognising the C-terminal
part of p53, we showed that the p40 corresponds to a truncated
form of p53. A similar pattern of translation products with p53
and p40 proteins was previously obtained when murine p53
mRNA was translated in vitro (20). According to Mosner et al.
(20), the p40 is a premature translation termination product,
but they did not explore the reasons for such a result.
By constructing two other recombinant strains y5′∆p53 and
y3′∆p53 harbouring plasmids containing the p53 cDNA minus
the 5′-UTR or the 154 bp of the 3′-UTR, respectively
(Fig. 4A), we showed that only the 5′-UTR was involved in the
translational control of p53. Indeed, no quantitative differences
were observed at the p53 mRNA level, while at the protein
level, the p53 full-length protein was detected only in the
y5′∆p53 strain at a high level, concomitant with a low level of
the p40 and only the truncated form (p40) was present in
y3′∆p53 at a low level of expression (Fig. 4B). This indicated
that: (i) the 3′-UTR is not involved in the generation of the
shorter form of p53 or in the level of expression; (ii) the effect
on the expression level and the protein length are connected.
The 5′-UTR is responsible for both effects, with the partici-
pation of a distal part of the coding sequence since even in the
absence of 5′-UTR, the truncated form exists.
Here, we propose an explanation based on a certain structure
adopted by the mRNA in the absence and presence of the 5′-UTR
(see below and the model on Fig. 5). We suggest that a particular
structure could be established at the terminal part of the p53
ORF that consequently prevents the ribosome from completing
the p53 mRNA translation. In fact, in the absence of 5′-UTR,
this structure (probably a stem–loop) should have weak free
energy that could be easily overrun by the ribosome. In the
presence of the 5′-UTR, such a structure is stabilised (which
could be either a defolded or a structured form) leading to a
complex tertiary structure that cannot be read through by the
ribosome. Such a structure could be a ‘pseudoknot’ [Fig. 5A,
(1)] or a coaxial stacking of two adjacent stems [Fig. 5A, (2)].
Moreover, the engagement of the 5′-UTR in this structure
would have a negative effect on the initiation of translation
since it is already established that the eukaryotic ribosome has
to slide along the 5′-UTR to reach the initiator ATG codon.
Consequently, according to this model, in the absence of the
5′-UTR (Fig. 5B), the presence of the full-length p53 protein at
a much higher level than the p40 means that more complete
than incomplete translation occurred and reflects the fact that
the single ‘stem–loop’ structure is read through more often
than not. In the presence of the 5′-UTR, only the p40 could be
seen at a low level of expression, reflecting the negative effect
of the complex structure on both the initiation and progression
of translation.
Many results demonstrate the involvement of UTRs in trans-
lational control of gene expression (29). The importance of the
p53 5′-UTR in mediating translational control has been shown
for murine p53 where the authors gave much evidence to
support a model in which the wild-type p53 interacts with its
own mRNA by stabilising secondary structure in the 5′-UTR to
inhibit its translation (20). It is noteworthy that previous
analyses predicted a capacity of the p53 mRNA to form a
stable stem–loop structure between nucleotides –216 and –108
in exon 1 of the 5′-UTR and between –216 and +284 with a
calculated free energy of –56 and –170 kcal/mol, respectively
(20,30,31). Furthermore, it is well known that ‘stem–loop’
structures with free energies of about –50 kcal/mol inhibit
translation both in vivo (32) and in vitro (33). In addition, Nigro et
al. (24) have also reported the negative effect of the 5′-UTR on the
efficient expression of human p53 in yeast: they showed that an
improvement in protein expression and a negative effect on
growth resulted from the removal of the 5′-UTR.
Furthermore, specific sequences within the 3′-UTR have
also been shown to repress translation (34,35). Indeed, a
protein that binds specifically to the 3′-UTR of protamine
2 mRNA and represses its translation has been identified (36).
In the case of p53, it was shown that in leukaemic bast cells, the
p53 protein level does not correlate with the p53 mRNA
suggesting that the p53 gene might be regulated at the translational
level in AML cells (22). These authors have demonstrated by
in vitro transcription-translation experiments that the p53 3′-UTR
contains a negative regulatory domain (an Alu-like element).
In addition, the full-length p53 3′-UTR, when present in cis of
heterologous transcripts, repressed its translation (22). A nega-
tive regulatory element capable of inhibiting translation in vivo
resides on a 330 nt region at the end of the human p53 3′-UTR,
which interacts with RNA binding factors (23). Note that in all
our constructs, such an Alu-like element is absent from the 3′-
UTR part.
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